In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.
Overview of Rirentilimab
Lirentelimab (AK002) is being developed for the treatment of indolent systemic mastocytosis, chronic urticaria, atopic keratoconjunctivitis, vernal keratoconjunctivitis, peanut allergy, severe perennial allergic conjunctivitis and other diseases. The drug candidate is a humanized afucosylated anti-Siglec-8 monoclonal antibody (IgG1) administered via intravenous and subcutaneous routes. It works by targeting mast cells that express siglec-8 (sialic acid-binding Ig like lectin 8).
It is also being developed for the treatment of eosinophilic duodenitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic esophagitis, dermatoses, skin and pulmonary fibrosis.
Allakos is a clinical-stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells. The company studies the therapeutic area of eosinophilic gastrointestinal diseases, chronic inflammatory diseases associated with persistent gastrointestinal symptoms and increased numbers of mast cells in the body. Its products include AK002, an antibody directed against Siglec-8, an inhibitory receptor indicated for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic and mastocytosis disease. The company is discovering AK007 to treat immuno-oncology diseases. It works with universities and pharmaceutical companies. Allakos is headquartered in Redwood City, California, USA.
For complete information on Lirentelimab drug-specific PTSR and LoA scores, purchase the report here.